Search results for "cost"

showing 10 items of 5421 documents

Minimally-invasive temporary gastric stimulation: A pilot study to predict the outcome of electronic gastric stimulation with the Enterra™ system.

2018

Abstract Introduction Gastroparesis (GP) is defined as delayed gastric emptying (GE) without any obstruction of the pylorus. It can be divided into idiopathic, diabetic, post surgical and rare causes. Electronic gastric stimulation (EGS) – Enterra Medtronic™ – is a part of GP therapy. Although its positive impact has been reported in open label trials, randomized controlled trials failed in demonstrating a positive outcome. The aim of this pilot study was to establish a reliable prediction for permanent gastric stimulation. Patients and procedure 6 female patients underwent laparoscopic implantation of 2 temporary electrodes. The Enterra™ system was connected and taped to the skin. Baseline…

AdultMalePost surgicalGastric stimulationGastroparesisStimulationElectric Stimulation TherapyPilot Projectslaw.invention03 medical and health sciencesYoung Adult0302 clinical medicineRandomized controlled trialMedian follow-uplawCost SavingsmedicineHumansGastroparesisAgedHepatologyGastric emptyingbusiness.industryGastroenterologyMiddle Agedmedicine.diseasePylorusmedicine.anatomical_structureTreatment OutcomeGastric Emptying030220 oncology & carcinogenesisAnesthesia030211 gastroenterology & hepatologyFemaleLaparoscopybusinessDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Deep inspiration-induced changes in lung volume decrease with severity of asthma

2007

Summary We have previously reported that the magnitude of deep inspiration (DI)-induced bronchodilation is only slightly reduced in mild asthmatics, compared to healthy subjects. The aim of this study was to evaluate whether increased severity of asthma is associated with impairment in the ability of DI to induce changes in lung volume. Thirty-six consecutive asthmatics recruited from the Pulmonary and the Allergy Outpatient Clinics of the Institute of Respiratory Diseases of the University of Palermo were divided into 3 groups: Intermittent (I), Mild Persistent (MP) and Moderate–Severe (MS), based on GINA guidelines. Single dose methacholine (Mch) bronchoprovocations were performed in the …

AdultMalePulmonary and Respiratory MedicineAllergymedicine.medical_specialtyAdolescentVital CapacityBronchiSettore MED/10 - Malattie Dell'Apparato RespiratorioGastroenterologySeverity of Illness IndexBronchial Provocation TestsDrug Administration ScheduleLung inflationBronchoconstrictor Agents03 medical and health sciencesFEV1/FVC ratio0302 clinical medicineInternal medicineForced Expiratory VolumemedicineOutpatient clinicCorticosteroidsHumansLung volumesAlbuterol030212 general & internal medicineasthma deep inspiration lung functionMethacholine ChlorideAsthmaAgedMethacholinebusiness.industryRespiratory diseaseMiddle Agedmedicine.diseaseAsthma3. Good healthBronchodilator Agents030228 respiratory systemInhalationAnesthesiaSalbutamolMethacholineBronchodilationFemalebusinessmedicine.drugRespiratory Medicine
researchProduct

Budesonide increases TLR4 and TLR2 expression in Treg lymphocytes of allergic asthmatics

2015

Abstract Background Reduced innate immunity responses as well as reduced T regulatory activities characterise bronchial asthma. Objectives In this study the effect of budesonide on the expression of TLR4 and TLR2 in T regulatory lymphocyte sub-population was assessed. Methods TLR4 and TLR2 expression in total peripheral blood mononuclear cells (PBMC), in CD4+/CD25+ and in CD4+/CD25− was evaluated, by flow cytometric analysis, in mild intermittent asthmatics (n = 14) and in controls (n = 11). The in vitro effects of budesonide in modulating: TLR4 and TLR2 expression in controls and in asthmatics; IL-10 expression and cytokine release (IL-6 and TNF-α selected by a multiplex assay) in asthmati…

AdultMalePulmonary and Respiratory MedicineBudesonidemedicine.medical_treatmentLymphocyteIn Vitro TechniquesCorticosteroids; Immunoregulation; T lymphocytes; TLR; Adult; Asthma; Budesonide; Cytokines; Female; Flow Cytometry; Glucocorticoids; Humans; In Vitro Techniques; Interleukin-10; Leukocytes Mononuclear; Male; T-Lymphocytes Regulatory; Toll-Like Receptor 2; Toll-Like Receptor 4; Young Adult; Pulmonary and Respiratory Medicine; Pharmacology (medical); Biochemistry (medical); Medicine (all)T-Lymphocytes RegulatoryPeripheral blood mononuclear cellYoung AdultGlucocorticoidTLRT lymphocytemedicineCorticosteroidHumansPharmacology (medical)IL-2 receptorBudesonideCytokineGlucocorticoidsIn Vitro Techniquebusiness.industryMedicine (all)Biochemistry (medical)ImmunoregulationFlow CytometryAsthmaToll-Like Receptor 2Interleukin-10Toll-Like Receptor 4Interleukin 10TLR2Cytokinemedicine.anatomical_structureImmunologyLeukocytes MononuclearTLR4CytokinesFemalebusinessHumanmedicine.drugPulmonary Pharmacology & Therapeutics
researchProduct

Inhaled Corticosteroids and the Beneficial Effect of Deep Inspiration in Asthma

2005

Deep inspiration-induced bronchoprotection and bronchodilation are impaired in asthma. We evaluated the effect of inhaled glucocorticosteroids on these phenomena. Two groups of subjects with asthma, 9 with moderate/severe hyperresponsiveness to methacholine, and 12 with mild/borderline hyperresponsiveness to methacholine, received inhaled fluticasone (880 microg daily) for 12 weeks. Serial bronchoprovocations were performed at Weeks 0, 6, and 12. The impact of deep inspirations on the airway response to methacholine was evaluated on the basis of inspiratory vital capacity and FEV(1). Fluticasone produced a wide spectrum of changes in the beneficial effects of deep inspiration, but the mean …

AdultMalePulmonary and Respiratory MedicineRespiratory Therapymedicine.drug_classVital CapacityRespiratory physiologySettore MED/10 - Malattie Dell'Apparato RespiratorioCritical Care and Intensive Care MedicineSeverity of Illness IndexBronchial Provocation TestsBronchoconstrictor AgentsForced Expiratory VolumeIntensive careAdministration Inhalationlung inflation asthma treatmentBronchodilationmedicineHumansMethacholine ChlorideAgedFluticasoneAsthmaInhalationbusiness.industryMiddle Agedmedicine.diseaseAsthmaBronchodilator AgentsA. Asthma and Allergyrespiratory tract diseasesAndrostadienesInhalationAnesthesiaRespiratory MechanicsFluticasoneCorticosteroidFemaleMethacholineBronchial Hyperreactivitybusinessmedicine.drugAmerican Journal of Respiratory and Critical Care Medicine
researchProduct

Exhaled Nitric Oxide Measurement Is Not Useful for Predicting the Response to Inhaled Corticosteroids in Subjects With Chronic Cough

2009

Background Increased concentrations of exhaled nitric oxide (ENO) are identified predominantly in subjects with chronic cough due to conditions that habitually respond well to therapy with inhaled corticosteroids (ICSs). The aim of this study was to assess the usefulness of ENO in predicting the response to ICS therapy in subjects with chronic cough and to determine the relationship between either methacholine or adenosine 5′-monophosphate (AMP) responsiveness and the response to ICS therapy. Methods A total of 43 patients with chronic cough were studied. During the baseline period, ENO measurement, spirometry, and concentration-response studies with both methacholine and AMP were performed…

AdultMalePulmonary and Respiratory MedicineSpirometryAdolescentmedicine.drug_classNitric OxideCritical Care and Intensive Care MedicineSensitivity and SpecificityBronchial Provocation TestsFluticasone propionatePredictive Value of TestsAdministration InhalationmedicineHumansProspective StudiesMethacholine ChlorideAgedFluticasoneInhalationmedicine.diagnostic_testbusiness.industryMiddle AgedAdenosine MonophosphateBronchodilator AgentsAndrostadienesChronic coughCoughROC CurveSpirometryAnesthesiaChronic DiseaseExhaled nitric oxideFluticasoneCorticosteroidFemaleMethacholinemedicine.symptomCardiology and Cardiovascular Medicinebusinessmedicine.drugChest
researchProduct

Dose-Related Effect of Beclomethasone Dipropionate on Airway Responsiveness in Asthma

1990

The effects of twice daily inhaled beclomethasone dipropionate (BDP) at two dose levels (500 and 1,000 micrograms daily) on the airway responsiveness to inhaled histamine was evaluated by a randomized, single-blind, cross-over study in 10 patients with stable asthma. The 12-week study began with a 3-week run-in period of baseline treatment, which was continued unchanged throughout the study, and the two treatment periods were separated by a 3-week placebo period. Patients attended the laboratory every 3 weeks for spirometry and histamine inhalation tests to determine the provocative concentration of histamine causing a 20% fall in forced expiratory volume in 1 s (PC20 of FEV1). There was a …

AdultMalePulmonary and Respiratory MedicineSpirometryAllergymedicine.drug_classPlaceboRandom Allocationchemistry.chemical_compoundForced Expiratory VolumemedicineHumansLungAsthmaDose-Response Relationship DrugInhalationmedicine.diagnostic_testbusiness.industryAirway ResistanceBeclomethasoneBeclometasone dipropionateMiddle Agedrespiratory systemmedicine.diseaseAsthmachemistryAnesthesiaCorticosteroidFemalebusinessHistamineHistaminemedicine.drugRespiration
researchProduct

Reslizumab as add-on therapy in patients with refractory asthma

2020

### Key messages #### What is the key question? #### What is the bottom line? #### Why read on? Asthma is a common disease, affecting an estimated 334 million people worldwide, with considerable impact on quality of life and high associated costs.1–3 Asthma severity is assessed retrospectively from the level of treatment required to control symptoms and exacerbations. Approximately 5%–10% of patients with asthma are believed to suffer from severe disease.4 Patients with severe asthma typically require ongoing maintenance therapy with high-dose inhaled corticosteroid (ICS)/long-acting beta-agonist (LABA).2 Furthermore, systemic corticosteroids (SCS) are often required for potentially life-th…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentmedicine.drug_classCost-Benefit Analysislcsh:MedicineInflammationAntibodies Monoclonal HumanizedYoung Adult03 medical and health sciences0302 clinical medicineReslizumabQuality of lifeMaintenance therapyAdrenal Cortex HormonesInternal medicinemedicineHumans1506Anti-Asthmatic Agents030212 general & internal medicineChildAdrenergic beta-2 Receptor AgonistsPulmonary EosinophiliaAgedAsthmalcsh:RC705-779business.industrylcsh:Rlcsh:Diseases of the respiratory systemMiddle AgedEosinophilmedicine.diseaseAsthmarespiratory tract diseasesTreatment Outcomemedicine.anatomical_structure030228 respiratory systempulmonary eosinophiliaRegression AnalysisCorticosteroidFemalemedicine.symptombusinessmedicine.drugBMJ Open Respiratory Research
researchProduct

A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in pa…

2019

Abstract Introduction Mometasone furoate (MF) is the inhaled corticosteroid (ICS) component in the long-acting β2-agonist (LABA)/ICS fixed-dose combination of indacaterol/MF, delivered via Breezhaler®, in development for asthma. MF at low (80 μg) and high (320 μg) doses delivered via Breezhaler® is expected to be comparable to MF at low (200 μg) and high (800 μg) doses respectively, delivered via Twisthaler®. Methods This was a randomized, double-blind, double-dummy, four-week, parallel-group study of 739 adolescents and adults with persistent asthma. Eligible patients were receiving ICS treatment up to the maximum dose per day on a stable regimen for at least four weeks before screening. T…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentmedicine.drug_classUrologyMometasone furoateRandom AllocationYoung Adult03 medical and health sciences0302 clinical medicineDouble-Blind MethodAdrenal Cortex HormonesAdministration InhalationmedicineClinical endpointHumansPharmacology (medical)Anti-Asthmatic Agents030212 general & internal medicineAdverse effectLungAgedAsthmaAged 80 and overbusiness.industryBiochemistry (medical)Middle Agedmedicine.diseaseAsthmaDrug CombinationsRegimenTreatment Outcome030228 respiratory systemAsthma Control QuestionnaireCorticosteroidIndacaterolFemalebusinessMometasone Furoatemedicine.drugPulmonary Pharmacology & Therapeutics
researchProduct

Measurement of Fractional Exhaled Nitric Oxide: Comparison of Three Different Analysers

2019

<b><i>Background:</i></b> Fractional exhaled nitric oxide (FeNO) is a surrogate marker for airway inflammation, supporting the diagnostic pathway and treatment decisions for asthma patients. <b><i>Objectives:</i></b> Aim of this study was to compare the new analyser Vivatmo pro (Bosch, BV) with NIOX VERO (Circassia, CN) and CLD (Ecomedics, EC). <b><i>Methods:</i></b> In 100 asthmatics (median 53 years [range 20–87], 62% female, 86% on inhaled corticosteroids [mean 1,300 μg beclomethasone dipropionate or equivalent], 35% treated with biologics) 2 FeNO measurements per device were performed. Additionally, the success rate…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyVital CapacityAnalyserClinical InvestigationsUrologyInhaled corticosteroidsNitric OxideYoung Adult03 medical and health sciences0302 clinical medicineForced Expiratory VolumeHumansMedicineAnti-Asthmatic Agents030212 general & internal medicineAgedAsthmaAged 80 and overbusiness.industryAirway inflammationMiddle Agedrespiratory systemmedicine.diseaseAsthmarespiratory tract diseasesBreath Tests030228 respiratory systemExhaled nitric oxideFemaleTreatment decision makingbusinessRespiration
researchProduct

Specific allergen immunotherapy for the treatment of allergic asthma: a review of current evidence.

2017

Asthma is frequently associated with atopy, characterized by the production of specific immunoglobulin E in response to environmental allergens. Currently, two types of allergen immunotherapy (AIT) are used in clinical practice: subcutaneous and sublingual immunotherapy, both accepted as key components of the therapeutic repertoire for allergic rhinitis and conjunctivitis. However, their role in asthma remains controversial. The present document is aimed at providing the clinicians with a review of the evidence on the use of AIT in asthma, focusing on the most relevant aspects of its mechanism of action, its efficacy, and existing data on safety, tolerability, and cost-effectivity, both in …

AdultMaleSevere asthmaAllergyAllergen immunotherapymedicine.medical_specialtyEfficacyCost-effectiveness.Cost effectivenessImmunologyMEDLINEAtopy03 medical and health sciences0302 clinical medicineHypersensitivityAdultsImmunology and AllergyMedicineHumansIntensive care medicineChildChildrenAllergen immunotherapyAsthmabusiness.industryAsthma treatmentAllergensmedicine.diseaseAsthmaClinical trialSystematic review030228 respiratory systemDesensitization ImmunologicSLIT030220 oncology & carcinogenesisImmunologyFemaleSafetySCITbusinessJournal of investigational allergologyclinical immunology
researchProduct